GB201520959D0 - Bis-pyridazine compounds and their use in treating cancer - Google Patents

Bis-pyridazine compounds and their use in treating cancer

Info

Publication number
GB201520959D0
GB201520959D0 GBGB1520959.6A GB201520959A GB201520959D0 GB 201520959 D0 GB201520959 D0 GB 201520959D0 GB 201520959 A GB201520959 A GB 201520959A GB 201520959 D0 GB201520959 D0 GB 201520959D0
Authority
GB
United Kingdom
Prior art keywords
bis
treating cancer
pyridazine compounds
pyridazine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1520959.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASTRAZENECA AND CANCER RES TECHNOLOGY Ltd AB
Original Assignee
ASTRAZENECA AND CANCER RES TECHNOLOGY Ltd AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASTRAZENECA AND CANCER RES TECHNOLOGY Ltd AB filed Critical ASTRAZENECA AND CANCER RES TECHNOLOGY Ltd AB
Priority to GBGB1520959.6A priority Critical patent/GB201520959D0/en
Publication of GB201520959D0 publication Critical patent/GB201520959D0/en
Priority to US15/360,332 priority patent/US10196382B2/en
Priority to ES16801774T priority patent/ES2806723T3/es
Priority to KR1020187017944A priority patent/KR20180083426A/ko
Priority to TW105138848A priority patent/TW201731837A/zh
Priority to CA3005102A priority patent/CA3005102A1/en
Priority to JP2018526706A priority patent/JP2018535226A/ja
Priority to AU2016360970A priority patent/AU2016360970B2/en
Priority to CN201680064313.0A priority patent/CN108349951B/zh
Priority to MX2018006374A priority patent/MX2018006374A/es
Priority to RU2018122012A priority patent/RU2018122012A/ru
Priority to PCT/EP2016/078899 priority patent/WO2017089587A1/en
Priority to DK16801774.7T priority patent/DK3380468T3/da
Priority to SG11201803814SA priority patent/SG11201803814SA/en
Priority to EP16801774.7A priority patent/EP3380468B8/en
Priority to ARP160103650A priority patent/AR106849A1/es
Priority to IL259358A priority patent/IL259358A/en
Priority to US16/266,361 priority patent/US10577354B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1520959.6A 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer Ceased GB201520959D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer
US15/360,332 US10196382B2 (en) 2015-11-27 2016-11-23 bis-Pyridazine compounds and their use in treating cancer
EP16801774.7A EP3380468B8 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer
CN201680064313.0A CN108349951B (zh) 2015-11-27 2016-11-25 双哒嗪化合物
PCT/EP2016/078899 WO2017089587A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer
TW105138848A TW201731837A (zh) 2015-11-27 2016-11-25 雙嗒 化合物及它們在治療癌症中之用途
CA3005102A CA3005102A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer
JP2018526706A JP2018535226A (ja) 2015-11-27 2016-11-25 ビス−ピリダジン化合物およびがんの治療におけるその使用
AU2016360970A AU2016360970B2 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer
ES16801774T ES2806723T3 (es) 2015-11-27 2016-11-25 Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
MX2018006374A MX2018006374A (es) 2015-11-27 2016-11-25 Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
RU2018122012A RU2018122012A (ru) 2015-11-27 2016-11-25 БИС-пиридазиновые соединения и их применение в лечении рака
KR1020187017944A KR20180083426A (ko) 2015-11-27 2016-11-25 비스-피리다진 화합물 및 암 치료에서 이의 용도
DK16801774.7T DK3380468T3 (da) 2015-11-27 2016-11-25 Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer
SG11201803814SA SG11201803814SA (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer
ARP160103650A AR106849A1 (es) 2015-11-27 2016-11-29 Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
IL259358A IL259358A (en) 2015-11-27 2018-05-14 Bis-pyridazine compounds and their use in treating cancer
US16/266,361 US10577354B2 (en) 2015-11-27 2019-02-04 Bis-pyridazine compounds and their use in treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
GB201520959D0 true GB201520959D0 (en) 2016-01-13

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1520959.6A Ceased GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer

Country Status (17)

Country Link
US (2) US10196382B2 (cg-RX-API-DMAC7.html)
EP (1) EP3380468B8 (cg-RX-API-DMAC7.html)
JP (1) JP2018535226A (cg-RX-API-DMAC7.html)
KR (1) KR20180083426A (cg-RX-API-DMAC7.html)
CN (1) CN108349951B (cg-RX-API-DMAC7.html)
AR (1) AR106849A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016360970B2 (cg-RX-API-DMAC7.html)
CA (1) CA3005102A1 (cg-RX-API-DMAC7.html)
DK (1) DK3380468T3 (cg-RX-API-DMAC7.html)
ES (1) ES2806723T3 (cg-RX-API-DMAC7.html)
GB (1) GB201520959D0 (cg-RX-API-DMAC7.html)
IL (1) IL259358A (cg-RX-API-DMAC7.html)
MX (1) MX2018006374A (cg-RX-API-DMAC7.html)
RU (1) RU2018122012A (cg-RX-API-DMAC7.html)
SG (1) SG11201803814SA (cg-RX-API-DMAC7.html)
TW (1) TW201731837A (cg-RX-API-DMAC7.html)
WO (1) WO2017089587A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106552296B (zh) 2015-09-29 2020-08-14 上海氪励铵勤科技发展有限公司 纳米粒子、其制备方法与结石取出装置及应用
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
KR20250137464A (ko) 2024-03-11 2025-09-18 이석재 숏블라스트머신의 연마재탱크

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402305WA (en) 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105960405B (zh) 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
EP3380468A1 (en) 2018-10-03
SG11201803814SA (en) 2018-06-28
IL259358A (en) 2018-07-31
AR106849A1 (es) 2018-02-21
US20190169172A1 (en) 2019-06-06
CA3005102A1 (en) 2017-06-01
US10577354B2 (en) 2020-03-03
EP3380468B8 (en) 2020-11-04
EP3380468B1 (en) 2020-05-20
CN108349951B (zh) 2020-11-13
US20170152244A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
ES2806723T3 (es) 2021-02-18
RU2018122012A (ru) 2019-12-30
JP2018535226A (ja) 2018-11-29
CN108349951A (zh) 2018-07-31
TW201731837A (zh) 2017-09-16
AU2016360970B2 (en) 2019-11-07
US10196382B2 (en) 2019-02-05
AU2016360970A1 (en) 2018-07-05
WO2017089587A1 (en) 2017-06-01
DK3380468T3 (da) 2020-07-27
KR20180083426A (ko) 2018-07-20

Similar Documents

Publication Publication Date Title
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
IL258953A (en) Dihydroimidazopyrazinone derivatives are useful for the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
GB201511382D0 (en) Novel compounds and their use in therapy
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
GB201420533D0 (en) Use of Nanomaterials in treating cancer
EP3736275C0 (en) PRODRUGS OF OXABICYCLOHEPTANE FOR USE IN THE TREATMENT OF CANCER
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
IL262143A (en) Improvements in cancer treatment
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL255541A (en) Cabazitaxel and its use for treating cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)